1. |
She J, Yang P, Hong Q, et al. Lung cancer in China: challenges and interventions. Chest 2013, 143(4): 1117-1126.
|
2. |
Torre LA, Bray F, Siegel RL, et al. CA Cancer J Clin, 2015, 65(2):87-108.
|
3. |
Johnson DH, Schiller JH, Bunn PA, Jr. Recent clinical advances in lung cancer management. J Clin Oncol 2014, 32(10):973-982.
|
4. |
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol, 2016, 11(1): 39-51.
|
5. |
Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol, 2015, 10(12): 1675-1684.
|
6. |
Wang X, Yan S, Lv C, et al. Impact of omission of intrapulmonary lymph node retrieval on outcome evaluation of lung cancer patients without lymph node metastasis: a propensity score matching analysis. Clin Lung Cancer, 2017, 18(6): e411-e416.
|
7. |
Maeshima AM, Tsuta K, Asamura H, et al. Prognostic implication of metastasis limited to segmental (level 13) and/or subsegmental (level 14) lymph nodes in patients with surgically resected nonsmall cell lung carcinoma and pathologic N1 lymph node status. Cancer 2012, 118(18): 4512-4518.
|
8. |
Smeltzer MP, Faris N, Yu X, et al. Missed intrapulmonary lymph node metastasis and survival after resection of non-small cell lung cancer. Ann Thorac Surg, 2016, 102(2): 448-453.
|
9. |
Osarogiagbon RU, Ray MA, Faris NR, et al. Prognostic value of national comprehensive cancer network lung cancer resection quality criteria. Ann Thorac Surg, 2017, 103(5): 1557-1565.
|
10. |
David EA, Cooke DT, Chen Y, et al. Does lymph node count influence survival in surgically resected non-small cell lung cancer?Ann Thorac Surg, 2017, 103(1): 226-235.
|
11. |
Yeh YC, Kadota K, Nitadori J, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma. Eur J Cardiothorac Surg, 2016, 49(1): e9-e15.
|
12. |
Bille A, Woo KM, Ahmad U, et al. Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients. Eur J Cardiothorac Surg, 2017, 51(4): 674-679.
|
13. |
Kanzaki R, Higashiyama M, Fujiwara A, et al. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study. Lung Cancer, 2011, 71(3): 333-337.
|
14. |
Xu YP, Li B, Xu XL, et al. Is there a survival benefit in patients with stage IIIA (N2) non-small cell lung cancer receiving neoadjuvant chemotherapy and/or radiotherapy prior to surgical resection: a systematic review and meta-analysis. Medicine (Baltimore), 2015, 94(23): e879.
|
15. |
Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl): e314S-e340S.
|
16. |
Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(13):2181-2190.
|
17. |
Chang JY, Kestin LL, Barriger RB, et al. ACR appropriateness criteria(R) nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent. Oncology (Williston Park), 2014, 28(8):706-710, 712, 714.
|